Merit Medical Launches the Resilience Through-the-Scope Esophageal Stent
New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures
Merit Medical’s Fred Lampropoulos Honored by Nasdaq
Merit Medical’s Fred Lampropoulos Honored by Nasdaq
Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty (PTA) through 24 months
Merit Medical Signs Asset Purchase Agreement with PENTAX Medical to Acquire C2 CryoBalloon Technology
Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders.
Merit Medical Announces SCOUT Milestone: 750,000 Patients Treated with Wire-Free Technology
SCOUT Radar Localization use grows, supporting more successful surgeries and improved patient care.
Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology
Thin-wall design with superior insertion and unique sheath-securement solution to support successful radial access procedures and may aid in reducing arterial spasm and occlusion
Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.
Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)
Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
Merit Medical Rings Nasdaq Opening Bell to Celebrate 35-Year Partnership
First Patient Enrolled in Merit Medical’s PREEMIE Study
Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants
Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis
Unique cell-impermeable1 design extends life-saving treatment for dialysis patients.
